Antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo

Y. Saikawa, T. Kubota, T. H. Kuo, Toshiharu Furukawa, S. Kase, H. Tanino, K. Ishibiki, M. Kitajima, R. M. Hoffman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin (pirarubicin; THP) was assessed using human gastric cancer cell lines in vitro and in vivo. The cytotoxicity of THP on MKN-28 and MKN-45 was superior to that of adriamycin (ADM) as detected by a growth assay with an MTT colorimetric endpoint. When the same doses of THP and ADM were administered intraperitoneally to nude mice bearing St-15, St-40 and SC-1-NU, the antitumor activity of THP was almost equivalent to ADM in terms of relative mean tumor weight. However, the adverse effects of THP were also significantly lower than those of ADM in terms of death rate, body weight loss and spleen weight loss. This was also confirmed in THP or ADM combination chemotherapy with mitomycin C and 5-fluorouracil on St-15 and MKN-45. These results indicated that THP is a candidate anthracycline to replace ADM for combination cancer chemotherapy in gastric carcinoma.

Original languageEnglish
Pages (from-to)469-473
Number of pages5
JournalAnticancer Research
Volume14
Issue number2 A
Publication statusPublished - 1994

Fingerprint

Doxorubicin
Stomach Neoplasms
Cell Line
Combination Drug Therapy
Weight Loss
Anthracyclines
Mitomycin
Tumor Burden
Nude Mice
Fluorouracil
Stomach
Spleen
Body Weight
Carcinoma
Mortality
pirarubicin
In Vitro Techniques
Growth
Neoplasms

Keywords

  • Adriamycin
  • Human gastric cancer
  • Pirarubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Saikawa, Y., Kubota, T., Kuo, T. H., Furukawa, T., Kase, S., Tanino, H., ... Hoffman, R. M. (1994). Antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo. Anticancer Research, 14(2 A), 469-473.

Antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo. / Saikawa, Y.; Kubota, T.; Kuo, T. H.; Furukawa, Toshiharu; Kase, S.; Tanino, H.; Ishibiki, K.; Kitajima, M.; Hoffman, R. M.

In: Anticancer Research, Vol. 14, No. 2 A, 1994, p. 469-473.

Research output: Contribution to journalArticle

Saikawa, Y, Kubota, T, Kuo, TH, Furukawa, T, Kase, S, Tanino, H, Ishibiki, K, Kitajima, M & Hoffman, RM 1994, 'Antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo', Anticancer Research, vol. 14, no. 2 A, pp. 469-473.
Saikawa, Y. ; Kubota, T. ; Kuo, T. H. ; Furukawa, Toshiharu ; Kase, S. ; Tanino, H. ; Ishibiki, K. ; Kitajima, M. ; Hoffman, R. M. / Antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo. In: Anticancer Research. 1994 ; Vol. 14, No. 2 A. pp. 469-473.
@article{9d2d3d1130ea4623ad7195f54ccc1cc9,
title = "Antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo",
abstract = "The antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin (pirarubicin; THP) was assessed using human gastric cancer cell lines in vitro and in vivo. The cytotoxicity of THP on MKN-28 and MKN-45 was superior to that of adriamycin (ADM) as detected by a growth assay with an MTT colorimetric endpoint. When the same doses of THP and ADM were administered intraperitoneally to nude mice bearing St-15, St-40 and SC-1-NU, the antitumor activity of THP was almost equivalent to ADM in terms of relative mean tumor weight. However, the adverse effects of THP were also significantly lower than those of ADM in terms of death rate, body weight loss and spleen weight loss. This was also confirmed in THP or ADM combination chemotherapy with mitomycin C and 5-fluorouracil on St-15 and MKN-45. These results indicated that THP is a candidate anthracycline to replace ADM for combination cancer chemotherapy in gastric carcinoma.",
keywords = "Adriamycin, Human gastric cancer, Pirarubicin",
author = "Y. Saikawa and T. Kubota and Kuo, {T. H.} and Toshiharu Furukawa and S. Kase and H. Tanino and K. Ishibiki and M. Kitajima and Hoffman, {R. M.}",
year = "1994",
language = "English",
volume = "14",
pages = "469--473",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 A",

}

TY - JOUR

T1 - Antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo

AU - Saikawa, Y.

AU - Kubota, T.

AU - Kuo, T. H.

AU - Furukawa, Toshiharu

AU - Kase, S.

AU - Tanino, H.

AU - Ishibiki, K.

AU - Kitajima, M.

AU - Hoffman, R. M.

PY - 1994

Y1 - 1994

N2 - The antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin (pirarubicin; THP) was assessed using human gastric cancer cell lines in vitro and in vivo. The cytotoxicity of THP on MKN-28 and MKN-45 was superior to that of adriamycin (ADM) as detected by a growth assay with an MTT colorimetric endpoint. When the same doses of THP and ADM were administered intraperitoneally to nude mice bearing St-15, St-40 and SC-1-NU, the antitumor activity of THP was almost equivalent to ADM in terms of relative mean tumor weight. However, the adverse effects of THP were also significantly lower than those of ADM in terms of death rate, body weight loss and spleen weight loss. This was also confirmed in THP or ADM combination chemotherapy with mitomycin C and 5-fluorouracil on St-15 and MKN-45. These results indicated that THP is a candidate anthracycline to replace ADM for combination cancer chemotherapy in gastric carcinoma.

AB - The antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin (pirarubicin; THP) was assessed using human gastric cancer cell lines in vitro and in vivo. The cytotoxicity of THP on MKN-28 and MKN-45 was superior to that of adriamycin (ADM) as detected by a growth assay with an MTT colorimetric endpoint. When the same doses of THP and ADM were administered intraperitoneally to nude mice bearing St-15, St-40 and SC-1-NU, the antitumor activity of THP was almost equivalent to ADM in terms of relative mean tumor weight. However, the adverse effects of THP were also significantly lower than those of ADM in terms of death rate, body weight loss and spleen weight loss. This was also confirmed in THP or ADM combination chemotherapy with mitomycin C and 5-fluorouracil on St-15 and MKN-45. These results indicated that THP is a candidate anthracycline to replace ADM for combination cancer chemotherapy in gastric carcinoma.

KW - Adriamycin

KW - Human gastric cancer

KW - Pirarubicin

UR - http://www.scopus.com/inward/record.url?scp=0028177713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028177713&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 469

EP - 473

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 A

ER -